Latest & greatest articles for valsartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on valsartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on valsartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for valsartan

41. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial

Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial 23247302 2013 01 22 2013 04 09 2015 11 19 1524-4539 127 3 2013 Jan 22 Circulation Circulation Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. 322-30 10.1161/CIRCULATIONAHA.112.135392 The role of angiotensin II receptor blockers in patients with a systemic right ventricle has not been elucidated. We (...) conducted a multicenter, double-blind, parallel, randomized controlled trial of angiotensin II receptor blocker valsartan 160 mg twice daily compared with placebo in patients with a systemic right ventricle caused by congenitally or surgically corrected transposition of the great arteries. The primary end point was change in right ventricular ejection fraction during 3-year follow-up, determined by cardiovascular magnetic resonance imaging or, in patients with contraindication

EvidenceUpdates2013

42. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching

Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Cost-effectiveness analysis of valsartan versus losartan and the effect of switching Baker TM, Goh J, Johnston A, Falvey H, Brede Y, Brown RE Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of valsartan, compared with losartan, and the impact of switching patients from valsartan to generic losartan, to lower blood pressure and prevent cardiovascular disease. The authors concluded that valsartan appeared to be cost-effective, compared with switching to generic losartan. Overall the quality of the study was adequate

NHS Economic Evaluation Database.2012

43. Valsartan (Diovan®)

Valsartan (Diovan®) Valsartan (Diovan®) Valsartan (Diovan®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Valsartan (Diovan®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat (...) Assessment Report Advice No. 0211. 2011 Authors' conclusions Valsartan (Diovan®) tablets are not recommended for use within NHS Wales for the treatment of hypertension in children and adolescents 6 to 18 years of age. The submission contained insufficient evidence for AWMSG to recommend its use. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antihypertensive Agentss; Hypertension; Valine Language Published English Country of organisation Wales English summary An English

Health Technology Assessment (HTA) Database.2011

44. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea

Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea 20522795 2010 10 01 2010 10 21 2015 11 19 1535-4970 182 7 2010 Oct 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. 954-60 10.1164/rccm.200912-1803OC Randomized controlled trials (RCTs) have shown that continuous positive airway pressure (...) (CPAP) treatment of obstructive sleep apnea (OSA) reduces blood pressure (BP). CPAP treatment has never been compared with antihypertensive medications in an RCT. To assess the respective efficacy of CPAP and valsartan in reducing BP in hypertensive patients with OSA never treated for either condition. In this 8-week randomized controlled crossover trial, 23 hypertensive patients (office systolic BP/diastolic BP: 155 ± 14/102 ± 11 mm Hg) with OSA (age, 57 ± 8 yr; body mass index, 28 ± 5 kg/m(2

EvidenceUpdates2010

45. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study

Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study 20716145 2010 08 18 2011 11 23 2015 11 19 1742-1241 64 10 2010 Sep International journal of clinical practice Int. J. Clin. Pract. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. 1367-74 10.1111/j.1742-1241.2010.02480.x A majority of hypertensive patients require > or = 2 agents to achieve target (...) blood pressure (BP). This 52-week, multicentre, open-label, randomised extension trial to a previously reported double-blind, placebo-controlled study evaluated the safety and efficacy of amlodipine/valsartan (Aml/Val) combination. Patients who successfully completed the core study without serious drug-related adverse events (AEs) and mean sitting systolic BP (MSSBP)/mean sitting diastolic BP (MSDBP) < or = 150/95 mmHg were eligible to enter the extension and be treated with Aml/Val 2.5/80 or 5/80

EvidenceUpdates2010

46. A systematic review and meta-analysis of telmisartan vs valsartan in the management of essential hypertension

A systematic review and meta-analysis of telmisartan vs valsartan in the management of essential hypertension A systematic review and meta-analysis of telmisartan vs valsartan in the management of essential hypertension A systematic review and meta-analysis of telmisartan vs valsartan in the management of essential hypertension Zheng Z, Lin S, Shi H CRD summary This review found no significant differences between telmisartan and valsartan in reducing diastolic or systolic blood (...) pressure, achieving target blood pressure or adverse events in patients with abnormally high blood pressure (essential hypertension); telmisartan combined with hydrochlorothiazide was more effective in reducing blood pressure. The generally high variation within the limited evidence presented makes the reliability of these conclusions unclear. Authors' objectives To compare the safety and effectiveness of telmisartan versus valsartan in the management of blood pressure in patients with essential hypertension

DARE.2010

47. Effect of valsartan on the incidence of diabetes and cardiovascular events.

Effect of valsartan on the incidence of diabetes and cardiovascular events. 20228403 2010 04 22 2010 04 27 2016 08 03 1533-4406 362 16 2010 Apr 22 The New England journal of medicine N. Engl. J. Med. Effect of valsartan on the incidence of diabetes and cardiovascular events. 1477-90 10.1056/NEJMoa1001121 It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. In this double-blind (...) , randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development

NEJM2010

48. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic Markov model

The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic Markov model The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic Markov model The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic Markov model Pradelli L, Iannazzo S, Zaniolo O Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of valsartan in patients aged 45 years or older, who had chronic heart failure, with a low (<40%) left ventricular ejection fraction. Valsartan was likely to be an effective and economically attractive addition to therapy

NHS Economic Evaluation Database.2009

49. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors

An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors Taylor M, Scuffham P A, Chaplin S, Papo N L Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of valsartan for the treatment after myocardial infarction of patients with left ventricular systolic dysfunction, heart failure, or both, who were not suitable for treatment with angiotensin-converting enzyme inhibitors

NHS Economic Evaluation Database.2009

50. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach Nixon RM, Muller E, Lowy A, Falvey H CRD summary The review compared the effectiveness of valsartan with other angiotensin II receptor blockers in reducing (...) systolic and diastolic blood pressure in essential hypertension. Valsartan at doses of 160 or 350mg/day was more effective than 100mg/day losartan and had comparable antihypertensive efficacy to other angiotensin II receptor blockers. The authors’ conclusions are unlikely to be reliable given limitations in the analysis. Authors' objectives To compare the effectiveness of valsartan with other angiotensin II receptor blockers in reducing systolic and diastolic blood pressure in essential hypertension

DARE.2009

52. Valsartan for prevention of recurrent atrial fibrillation.

Valsartan for prevention of recurrent atrial fibrillation. 19369667 2009 04 16 2009 04 20 2015 11 19 1533-4406 360 16 2009 Apr 16 The New England journal of medicine N. Engl. J. Med. Valsartan for prevention of recurrent atrial fibrillation. 1606-17 10.1056/NEJMoa0805710 Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling (...) , and some clinical studies suggest that they may prevent atrial fibrillation. We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had

NEJM2009

56. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. 17467513 2007 04 30 2007 05 10 2015 11 19 1474-547X 369 9571 2007 Apr 28 Lancet (London, England) Lancet Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. 1431-9 Drugs that inhibit the renin (...) -angiotensin-aldosterone system benefit patients at risk for or with existing cardiovascular disease. However, evidence for this effect in Asian populations is scarce. We aimed to investigate whether addition of an angiotensin receptor blocker, valsartan, to conventional cardiovascular treatment was effective in Japanese patients with cardiovascular disease. We initiated a multicentre, prospective, randomised controlled trial of 3081 Japanese patients, aged 20-79 years, (mean 65 [SD 10] years) who were

Lancet2007

57. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. 17658393 2007 07 30 2007 08 09 2015 11 19 1474-547X 370 9583 2007 Jul 21 Lancet (London, England) Lancet Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. 221-9 The aim of this study was to assess dual renin system intervention with the maximum recommended doses of aliskiren and valsartan (...) , compared with each drug alone in patients with hypertension. In this double-blind study, 1797 patients with hypertension (mean sitting diastolic blood pressure 95-109 mm Hg and 8-h daytime ambulatory diastolic blood pressure > or =90 mm Hg) were randomly assigned to receive once-daily aliskiren 150 mg (n=437), valsartan 160 mg (455), a combination of aliskiren 150 mg and valsartan 160 mg (446), or placebo (459) for 4 weeks, followed by forced titration to double the dose to the maximum recommended dose

Lancet2007

58. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis

Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Smith D G, Cerulli A, Frech F H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the addition of valsartan to usual care for the treatment of heart failure (HF) in patients not taking angiotensin-converting enzyme (ACE) inhibitors because of side effects or contraindications. Valsartan was given at a starting dose of 40 mg twice daily and titrated to a target

NHS Economic Evaluation Database.2005

60. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria

Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with Type 2 diabetes and microalbuminuria Smith D G, Nguyen A B, Peak C N (...) , Frech F H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two treatment options for patients with Type 2 diabetes and microalbuminuria. The treatment options were the angiotensin II receptor blocker valsartan

NHS Economic Evaluation Database.2004